Omega-3 may reduce heart patients’ hospital stay, study finds

By Will Chu

- Last updated on GMT

'The reduced length of hospital stay in this study was associated with the tendency of the omega-3 group to experience a reduction in postoperative atrial fibrillation.'  (© iStock.com)
'The reduced length of hospital stay in this study was associated with the tendency of the omega-3 group to experience a reduction in postoperative atrial fibrillation.' (© iStock.com)

Related tags: Omega-3 polyunsaturated fatty, Myocardial infarction, Essential fatty acid, Nutrition

Cardiac surgery patients given omega-3 polyunsaturated fatty acids (PUFAs) beforehand found their hospital stay reduced by up to 2.4 days, an analysis has suggested. 

The omega-3 supplementation also reduced post-operative cardiac complications such as experiencing an irregular heartbeat.

The findings imply that increasing the intake of omega-3s result in reduction in hospital utilisation and overall healthcare costs, adding to existing evidence that points to the supplement’s anti-inflammatory and anti-arrhythmic properties.

Study details

A meta-analysis, published in Clinical Nutrition, ​focused on 11 RCT's with 1038 patients. No effect of omega-3 PUFA on the primary outcome - length of stay (LOS) in the intensive care unit (ICU) - was found.

The changes were found in the secondary outcomes - LOS and postoperative atrial fibrillation (POAF) incidence. No effects were found on mortality or MV duration.

"Omega-3s are well known for their benefits on cardiovascular health, including a reduced risk of arrhythmias and reduced mortality in patients with recent myocardial infarction or cardiac failure,"​ said co-author Dr Pascal Langlois from Sherbrooke University.

"Furthermore, they exhibit interesting anti-inflammatory properties and modulate the immune system."

doctor hospital
The findings imply that increasing the intake of omega-3 oils result in reduction in hospital utilisation and overall healthcare costs. (© iStock.com)

Several randomised controlled trials​ (RCT) have found contradictory​ results for pre-operative omega-3 PUFA administration.

However, other studies have found that pre-operative omega-3-PUFA could be a promising strategy to control the responses to cardiac surgery.

“The reduced length of hospital stay in this study was associated with the tendency of the omega-3 group to experience a reduction in postoperative atrial fibrillation,”​ said the study’s authors.

“The exact mechanism associated with this benefit is unknown, but it is widely believed to be due to the omega-3s' anti-inflammatory and anti-arrhythmic properties."

Source: Clinical Nutrition

Published online ahead of print, doi:10.1016/j.clnu.2016.05.013

“Omega-3 polyunsaturated fatty acids in cardiac surgery patients: An updated systematic review and meta-analysis.”

Authors: Pascal Langlois, Gil Hardy, William Manzanares

Related news

Related products

show more

Does my Nutraceutical Need a Clinical Trial?

Does my Nutraceutical Need a Clinical Trial?

dicentra – CRO and regulatory consulting firm | 03-Aug-2020 | Technical / White Paper

The global nutraceutical industry is growing at an unprecedented rate. However, companies preparing to bring new and innovative products to the burgeoning...

Supporting cardiovascular health with probiotics

Supporting cardiovascular health with probiotics

Deerland Probiotics & Enzymes | 03-Aug-2020 | Technical / White Paper

Throughout the last decade, researchers have investigated the role of the gut microbiota in the development of cardiovascular disease. Evidence exists...

Related suppliers

Follow us

Products

View more

Webinars